Aesica Opens New High-Capacity Manufacturing Facility in Queenborough, UK - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Opens New High-Capacity Manufacturing Facility in Queenborough, UK


Aesica Pharmaceuticals, a CDMO specializing in formulated products and APIs, announced that it has built a new high-capacity manufacturing facility at its UK site in Queenborough, Kent. The company invested £30 million towards the 10,000 m2 expansion of the new facility, which has been constructed specifically for the production of solid dose medications used in the treatment of type II diabetes.

The facility, which will commence commercial production in November 2013, contains highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system.

Her Majesty’s Lord-Lieutenant of Kent, Viscount De L’Isle attended the opening ceremony of the new facility in recognition of Aesica’s contribution to the economy through the creation of new jobs following its commercial expansion. Aesica will recruit 55 technicians who will be trained on site. The design of the facility will allow the current capacity to be more than doubled in the future, which would open up another 50 jobs.

Source: Aesica

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here